Opinion Review
Copyright ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Aug 6, 2020; 8(15): 3156-3163
Published online Aug 6, 2020. doi: 10.12998/wjcc.v8.i15.3156
Medical research during the COVID-19 pandemic
Khalid AlNaamani, Siham AlSinani, Alan N Barkun
Khalid AlNaamani, Division of Gastroenterology, Department of Internal Medicine, Armed Forces Hospital, Muscat 999046, Oman
Siham AlSinani, Graduate Medical Education Department and Department of Child Health, Sultan Qaboos University Hospital, Muscat 999046, Oman
Alan N Barkun, Division of Gastroenterology, McGill University and the McGill University Health Centre, Montreal H3G1A4, Canada
Author contributions: ALNaamani K conceived the idea for the manuscript, reviewed the literature and drafted the manuscript; AlSinani S reviewed the literature and drafted the manuscript; Barkun AN critical revision and manuscript appraisal; The final version is approved by all authors.
Conflict-of-interest statement: The authors declare no conflict of interests.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Alan N Barkun, AGAF, FACG, FACP, FRCP (C), MD, MSc, Full Professor, Division of Gastroenterology, McGill University and the McGill University Health Centre, 1650 Cedar Avenue C7-200, Montreal H3G1A4, Canada. alan.barkun@muhc.mcgill.ca
Received: April 30, 2020
Peer-review started: April 30, 2020
First decision: May 21, 2020
Revised: May 22, 2020
Accepted: July 22, 2020
Article in press: July 22, 2020
Published online: August 6, 2020
Processing time: 97 Days and 19.8 Hours
Abstract

The current pandemic of coronavirus disease 2019 (COVID-19) which was first detected in Wuhan, China in December 2019 is caused by the novel coronavirus named severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). The virus has quickly spread to a large number of countries leading to a great number of deaths. Unfortunately, till today there is no specific treatment or vaccination for SARS-CoV-2. Most of the suggested treatment medications are based on in vitro laboratory investigations, experimental animal models, or previous clinical experience in treating similar viruses such as SARS-CoV-1 or other retroviral infections. The running of any clinical trial during a pandemic is affected at multiple levels. Reasons for this include patient hesitancy or inability to continue investigative treatments due to self-isolation/quarantine, or limited access to public places (including hospitals). Additional barriers relate to health care professionals being committed to other critical tasks or quarantining themselves due to contact with COVID-19 positive patients. The best research approaches are those that adapt to such external unplanned obstacles. Ongoing clinical trials before COVID-19 pandemic have the potential for identifying important therapies in the long-term if they can be completed as planned. However, these clinical trials may require modifications due a pandemic such as this one to ensure the rights, safety, and wellbeing of participants as well as medical staff involved in the conduction of clinical trials. Clinical trials initiated during the pandemic must be time-efficient and flexible due to high contagiousness of severe acute respiratory syndrome coronavirus 2, the significant number of reported deaths, and time constraints needed to perform high quality clinical trials, enrolling adequate sample sizes. Collaboration between different countries as well as implementation of innovative clinical trial designs are essential to successfully complete such initiatives during the current pandemic. Studies looking at the long term sequalae of COVID-19 are also of importance as recent publications describe multi-organ involvement. Long term follow-up of COVID-19 survivors is thus also important to identify possible physical and mental health sequellae.

Keywords: SARS-CoV-2, COVID-19, Pandemic, Research, Clinical trials

Core tip: Clinical research during coronavirus disease 2019 (COVID-19) is essential to provide high-quality timely critical diagnostic and therapeutic information. Collaborative work is encouraged to support limited resources countries and overcome public health crises in the future. Preventative and interventional measures should be prioritized. Ongoing studies having been initiated before the pandemics arise should be rigorously evaluated by trial sponsors. Priority during the pandemic should be given to completing timely clinical trials focusing on the management of COVID-19 patients.